Imaging

/Imaging

Comparing (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline PET/CT in Prostate Cancer Relapse

There has been a lot of hype and confusion about what is the best contrast for prostate cancer PET/CT scans. The two newest contrasts; (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline both have their supporters and their detractors. To try and evaluate the efficacy differences between these two contrasts in men who have suffered a bio-chemical recurrence after surgery researchers did a head to head evaluation of 100 consecutive men treated with surgery for prostate cancer and presenting with a rising PSA. All of the men had (11)C-choline and (18)F-FACBC PET/CTs performed within 1 week and were off hormonal therapy at the time [...]

PET/CT Scans More Sensitive Than CT and Bone Scans For Detecting Metastatic Prostate Cancer

According to an article in the Journal of Nuclear Medicine, researchers compared a PET/CT scan using the radiotracer F-18 DCFBC to conventional imaging modalities — an expanded Tc-99m-methylene diphosphonate (MDP) bone scan and contrast-enhanced CT of the chest, abdomen and pelvis — to detect prostate-specific membrane antigen (PSMA), which is associated with prostate cancer metastases. In a study of 17 men the researchers found that the F-18 DCFBC PET scans were able to detect a larger number of prostate cancer lesions than the other imaging modalities. The researchers found 592 positive lesions compared to 520 identified by the other methods. [...]

Predicting the Long-Term Survival of Men with A Biochemical Recurrence Post-Surgery Who Are Hormone Naive Can Change How We Treat Them

Appearing in the European Journal of Nuclear Medicine and Molecular Imaging a recent study provides data on the long-term survival of men with a biochemical recurrence after failed surgery. In the study by Giovacchini et al. it was shown that a PET/CT scan (specifically a [11C] choline PET/CT) could predict the long-term survival of men who are hormone-naive (not yet started ADT) who had a biochemical failure (where biochemical failure was defined by a PSA level > 0.2 ng/ml post surgery). The study was a retrospective analysis of  302 men who were hormone-naive and who had been previously treated with a [...]

Quality Control Of Xofigo – Confirming That Intravenous Radium-223 Actually Becomes Systemic and Doesn’t Leak At The Injection Site

Radium-223 dichloride (Xofigo) has been approved as an intravenous radiotherapy for men with castration-resistant prostate cancer (CRPC) who have multiple osseous (bone) metastases. Most often, it is used in men who have too many metastases to treat with spot radiation. Xofigo works by mimicking calcium that is attracted to bones. To be successful the drug must successfully circulate through out the body to be able to find all of the metastases. A recent study evaluated the ability of the intravenous introduction of the Xofigo to properly circulate through the body. The researchers relied on the fact that Xofigo in addition [...]